{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:27:17Z","timestamp":1790245637028,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00280-018-3618-4","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T05:38:18Z","timestamp":1531201098000},"page":"511-519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed\/refractory solid tumors"],"prefix":"10.1007","volume":"82","author":[{"given":"Junji","family":"Furuse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayasu","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Fujisaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Naruge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"3618_CR1","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291\u20133310","journal-title":"Oncogene"},{"key":"3618_CR2","first-page":"4682","volume":"49","author":"JL Bos","year":"1989","unstructured":"Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49:4682\u20134689","journal-title":"Cancer Res"},{"key":"3618_CR3","doi-asserted-by":"publisher","first-page":"8323","DOI":"10.1073\/pnas.86.21.8323","volume":"86","author":"PJ Casey","year":"1989","unstructured":"Casey PJ, Solski PA, Der CJ, Buss JE (1989) p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 86:8323\u20138327","journal-title":"Proc Natl Acad Sci USA"},{"key":"3618_CR4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Koc\u00e1kova I, Ruff P, B\u0142asi\u0144ska-Morawiec M, \u0160makal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab\u2013FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023\u20131034","journal-title":"N Engl J Med"},{"key":"3618_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11523-013-0271-z","volume":"8","author":"M Poulin-Costello","year":"2013","unstructured":"Poulin-Costello M, Azoulay L, Van Cutsem E, Peeters M, Siena S, Wolf M (2013) An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. Target Oncol 8:127\u2013136","journal-title":"Target Oncol"},{"key":"3618_CR6","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1038\/sj.onc.1202602","volume":"18","author":"B Weisz","year":"1999","unstructured":"Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben-Baruch G, Marciano D, Gierschik P, Kloog Y (1999) A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18:2579\u20132588","journal-title":"Oncogene"},{"key":"3618_CR7","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/(SICI)1097-0215(19990315)80:6<911::AID-IJC18>3.0.CO;2-4","volume":"80","author":"Y Egozi","year":"1999","unstructured":"Egozi Y, Weisz B, Gana-Weisz M, Ben-Baruch G, Kloog Y (1999) Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist. Int J Cancer 80:911\u2013918","journal-title":"Int J Cancer"},{"key":"3618_CR8","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s10637-012-9818-6","volume":"30","author":"D Laheru","year":"2012","unstructured":"Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao M, Song D, Rudek MA, Hidalgo M (2012) Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs 30:2391\u20132399","journal-title":"Invest New Drugs"},{"key":"3618_CR9","doi-asserted-by":"publisher","first-page":"22263","DOI":"10.1074\/jbc.270.38.22263","volume":"270","author":"M Marom","year":"1995","unstructured":"Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y, Kloog Y (1995) Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem 270:22263\u201322270","journal-title":"J Biol Chem"},{"key":"3618_CR10","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1021\/bi972032d","volume":"37","author":"R Haklai","year":"1998","unstructured":"Haklai R, Weisz MG, Elad G, Paz A, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y (1998) Dislodgment and accelerated degradation of Ras. Biochemistry 37:1306\u20131314","journal-title":"Biochemistry"},{"key":"3618_CR11","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/JTO.0b013e318223c099","volume":"6","author":"GJ Riely","year":"2011","unstructured":"Riely GJ, Johnson ML, Medina C, Rizvi NA, Miller VA, Kris MG, Pietanza MC, Azzoli CG, Krug LM, Pao W, Ginsberg MS (2011) A phase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutations. J Thorac Oncol 6:1435\u20131437","journal-title":"J Thorac Oncol"},{"key":"3618_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.clml.2015.02.018","volume":"15","author":"T Badar","year":"2015","unstructured":"Badar T, Cortes JE, Ravandi F, O\u2019Brien S, Verstovsek S, Garcia-Manero G, Kantarjian H, Borthakur G (2015) Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk 15:433\u2013438","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3618_CR13","unstructured":"International Conference on Harmonisation - safety guidance documents; S9 Nonclinical Evaluation for Anticancer Pharmaceuticals (2010) U.S. Department of Health and Human Services, Food and Drug Administration. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm085389.pdf\n                    \n                  . Accessed 30 Aug 2017"},{"key":"3618_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"3618_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00280-009-1027-4","volume":"65","author":"AM Tsimberidou","year":"2010","unstructured":"Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R (2010) Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol 65:235\u2013241","journal-title":"Cancer Chemother Pharmacol"},{"key":"3618_CR16","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626\u20131634","journal-title":"J Clin Oncol"},{"key":"3618_CR17","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1200\/JCO.2012.45.1492","volume":"31","author":"M Peeters","year":"2013","unstructured":"Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J (2013) Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 31:759\u2013765","journal-title":"J Clin Oncol"},{"key":"3618_CR18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrc3151","volume":"11","author":"N Berndt","year":"2011","unstructured":"Berndt N, Hamilton AD, Sebti SM (2011) Targeting protein prenylation for cancer therapy. Nat Rev Cancer 11:775\u2013791","journal-title":"Nat Rev Cancer"},{"key":"3618_CR19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","volume":"22","author":"E Cutsem Van","year":"2004","unstructured":"Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430\u20131438","journal-title":"J Clin Oncol"},{"key":"3618_CR20","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1200\/JCO.2004.10.037","volume":"22","author":"S Rao","year":"2004","unstructured":"Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T, Dostalova J, Illes A, Belly R, Perez-Ruixo JJ, Park YC, Palmer PA (2004) Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 22:3950\u20133957","journal-title":"J Clin Oncol"},{"key":"3618_CR21","doi-asserted-by":"publisher","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","volume":"272","author":"DB Whyte","year":"1997","unstructured":"Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK (1997) K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459\u201314464","journal-title":"J Biol Chem"},{"key":"3618_CR22","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/sj.onc.1201296","volume":"15","author":"EC Lerner","year":"1997","unstructured":"Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM (1997) Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15:1283\u20131288","journal-title":"Oncogene"},{"key":"3618_CR23","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","volume":"5","author":"F Skoulidis","year":"2015","unstructured":"Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV (2015) Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5:860\u2013877","journal-title":"Cancer Discov"},{"key":"3618_CR24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00262-017-2005-z","volume":"66","author":"N Chen","year":"2017","unstructured":"Chen N, Fang W, Lin Z, Peng P, Wang J, Zhan J, Hong S, Huang J, Liu L, Sheng J, Zhou T, Chen Y, Zhang H, Zhang L (2017) KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Cancer Immunol Immunother 66:1175\u20131187","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3618-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3618-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3618-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T07:30:45Z","timestamp":1562743845000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3618-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["3618"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3618-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"assertion":[{"value":"6 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Junji Furuse has received honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Yakult, Kyowa Hakko Kirin, Eli Lilly Japan, Ono Pharmaceutical, Eisai, Bayer Pharmaceutical, Zeria Pharmaceutical, Fujifilm, Merck Serono, Novartis, J-Pharma, Otsuka Pharmaceutical, Boehringer Ingelheim, Takeda Pharmaceutical, Daiichi Sankyo, Astra Zeneca, Astellas Pharma, Mitsubishi Tanabe Pharma, Bristol-Myers Squibb, MSD, Meiji Seika Pharma, Ajinomoto Pharmaceuticals, Nippon Kayaku, Sumitomo Dainippon Pharma, Sawai, Sandoz, Mochida Pharma and Shionogi, and research funding from Taiho Pharmaceutical, Ono Pharmaceutical, Onco Therapy Science, Merck Serono, Zeria Pharmaceutical, Eli Lilly Japan, Takeda Pharmaceutical, Chugai Pharmaceutical, Bayer Pharmaceutical, Glaxo Smith Kline, Yakult, Sumitomo Dainippon Pharma, Daiichi Sankyo, Shionogi, Novartis, Torii Pharma, J-Pharma, Nippon Kayaku, Bristol-Myers Squibb, Janssen Pharmaceutical, Sanofi, Kyowa Hakko Kirin, Mochida Pharma, Astellas Pharma, Hisamitsu Pharmaceutical and Pfizer. Takayasu Kurata has received honoraria from Ono Pharmaceutical. Naohiro Okano and Daisuke Naruge have received research funding from Taiho Pharmaceutical, Ono Pharmaceutical, Onco Therapy Science, Merck Serono, Zeria Pharmaceutical, Eli Lilly Japan, Takeda Pharmaceutical, Chugai Pharmaceutical, Bayer Pharmaceutical, Glaxo Smith Kline, Yakult, Sumitomo Dainippon Pharma, Daiichi Sankyo, Shionogi, Novartis, Torii Pharma, J-Pharma, Nippon Kayaku, Bristol-Myers Squibb, Janssen Pharmaceutical, Sanofi, Kyowa Hakko Kirin, Mochida Pharma, Astellas Pharma, Hisamitsu Pharmaceutical and Pfizer. Fumio Nagashima has received honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Kyowa Hakko Kirin, Merck Serono, Takeda Pharmaceutical, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Bristol-Myers Squibb, Nippon Kayaku and Sumitomo Dainippon Pharma, and research funding from Taiho Pharmaceutical, Ono Pharmaceutical, Onco Therapy Science, Merck Serono, Zeria Pharmaceutical, Eli Lilly Japan, Takeda Pharmaceutical, Chugai Pharmaceutical, Bayer Pharmaceutical, Glaxo Smith Kline, Yakult, Sumitomo Dainippon Pharma, Daiichi Sankyo, Shionogi, Novartis, Torii Pharma, J-Pharma, Nippon Kayaku, Bristol- Myers Squibb, Janssen Pharmaceutical, Sanofi, Kyowa Hakko Kirin, Mochida Pharma, Astellas Pharma, Hisamitsu Pharmaceutical and Pfizer. Kazuhiko Nakagawa has received honoraria from Astellas Pharma, AstraZeneca K.K., Chugai Pharmaceutical, Nippon Boehringer Ingelheim, Eli Lilly Japan K.K., Pfizer Japan and Novartis Pharma K.K., and research funding from Chugai Pharmaceutical, Astellas Pharma, MSD K.K., Ono Pharmaceutical, EPS Associates, Quintiles, Daiichi Sankyo, Japan Clinical Research Operations, Eisai, Kyowa Hakko Kirin, Pfizer Japan, Takeda Pharmaceutical, Nippon Boehringer Ingelheim, Bristol-Myers Squibb, and PPD-SNBL K.K.. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}